Limits...
Anti-nociceptive effects of elcatonin injection for postmenopausal women with back pain: a randomized controlled trial.

Ikegami S, Kamimura M, Uchiyama S, Nakagawa H, Hashidate H, Takahara K, Takahashi J, Kato H - Open Orthop J (2010)

Bottom Line: The mean VAS scores for the elcatonin group were then compared with those of the placebo group.There were no statistically significant differences in the mean VAS scores for pain at rest between the two groups during the 5-week treatment course.This analgesic effect continued for the subsequent 3 weeks.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.

ABSTRACT

Background: Eel calcitonin (elcatonin) injection is widely used for elderly patients suffering from somatic pain in Japan. However, there have been few reports on the analgesic effects of elcatonin injection. The purpose of this study was to examine the analgesic effects of elcatonin injection in postmenopausal women with lower back pain.

Methods: This study was designed as a double-blind, randomized, placebo-controlled study. Thirty-six women aged >/=50 years with acute lower back pain participated in this study. They were randomly divided into two treatment groups according to whether they received a placebo or a weekly trigger point injection of elcatonin (20 units). They were observed for 5 weeks and the extent of pain at motion and at rest according to the visual analog scale (VAS) was evaluated. The mean VAS scores for the elcatonin group were then compared with those of the placebo group.

Results: There were no statistically significant differences in the mean VAS scores for pain at rest between the two groups during the 5-week treatment course. However, the mean VAS scores for motion pain in the elcatonin group were significantly lower than those in the placebo group at the third, fifth and sixth weeks.

Conclusions: Elcatonin injection (20 units) significantly relieved motion pain in the lower back in postmenopausal women after three weeks of treatment. This analgesic effect continued for the subsequent 3 weeks.

No MeSH data available.


Related in: MedlinePlus

The extent of pain after the first injection of elcatonin or placebo. The means of the visual analogue scale value for each group are shown. Error bars indicate the standard error. *p < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2864422&req=5

Figure 2: The extent of pain after the first injection of elcatonin or placebo. The means of the visual analogue scale value for each group are shown. Error bars indicate the standard error. *p < 0.05.

Mentions: The patterns of pain at rest were very similar in the elcatonin and placebo groups (Fig. 2). The mean VAS scores were roughly 3.0 at the time of the first visit in each group (3.00 ± 2.60 in the elcatonin group, 2.83 ± 2.65 in the placebo group), and these values decreased over time, reaching nearly 0 in the fifth week (0.20 ± 0.35 in the elcatonin group, 0.34 ± 0.59 in the placebo group). There was a significant effect of the passage of time after the first visit, but there were no significant effect in regard to the type of injected drugs and no significant interaction between the drugs and the course of time (Table 3). In contrast, the course and extent of motion pain were not similar between the two groups. The mean VAS scores differed between the two groups, although the values in both groups decreased over time (Fig. 2). There were significant effects in regard to the time and the type of drug, but there was no significant interaction between these two factors (Table 3). Although the mean VAS scores of the two groups were similar at the time of first visit (6.91 ± 1.93 in the elcatonin group, 7.04 ± 2.44 in the placebo group), the mean VAS score of the elcatonin group decreased to a greater degree than that of the placebo group during the evaluation period. There was a statistically significant difference in the mean VAS scores between the two groups at the third (p = 0.047), fifth (p = 0.047) and sixth weeks (p = 0.023). No adverse events were observed during the course of the trial.


Anti-nociceptive effects of elcatonin injection for postmenopausal women with back pain: a randomized controlled trial.

Ikegami S, Kamimura M, Uchiyama S, Nakagawa H, Hashidate H, Takahara K, Takahashi J, Kato H - Open Orthop J (2010)

The extent of pain after the first injection of elcatonin or placebo. The means of the visual analogue scale value for each group are shown. Error bars indicate the standard error. *p < 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2864422&req=5

Figure 2: The extent of pain after the first injection of elcatonin or placebo. The means of the visual analogue scale value for each group are shown. Error bars indicate the standard error. *p < 0.05.
Mentions: The patterns of pain at rest were very similar in the elcatonin and placebo groups (Fig. 2). The mean VAS scores were roughly 3.0 at the time of the first visit in each group (3.00 ± 2.60 in the elcatonin group, 2.83 ± 2.65 in the placebo group), and these values decreased over time, reaching nearly 0 in the fifth week (0.20 ± 0.35 in the elcatonin group, 0.34 ± 0.59 in the placebo group). There was a significant effect of the passage of time after the first visit, but there were no significant effect in regard to the type of injected drugs and no significant interaction between the drugs and the course of time (Table 3). In contrast, the course and extent of motion pain were not similar between the two groups. The mean VAS scores differed between the two groups, although the values in both groups decreased over time (Fig. 2). There were significant effects in regard to the time and the type of drug, but there was no significant interaction between these two factors (Table 3). Although the mean VAS scores of the two groups were similar at the time of first visit (6.91 ± 1.93 in the elcatonin group, 7.04 ± 2.44 in the placebo group), the mean VAS score of the elcatonin group decreased to a greater degree than that of the placebo group during the evaluation period. There was a statistically significant difference in the mean VAS scores between the two groups at the third (p = 0.047), fifth (p = 0.047) and sixth weeks (p = 0.023). No adverse events were observed during the course of the trial.

Bottom Line: The mean VAS scores for the elcatonin group were then compared with those of the placebo group.There were no statistically significant differences in the mean VAS scores for pain at rest between the two groups during the 5-week treatment course.This analgesic effect continued for the subsequent 3 weeks.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto 390-8621, Japan.

ABSTRACT

Background: Eel calcitonin (elcatonin) injection is widely used for elderly patients suffering from somatic pain in Japan. However, there have been few reports on the analgesic effects of elcatonin injection. The purpose of this study was to examine the analgesic effects of elcatonin injection in postmenopausal women with lower back pain.

Methods: This study was designed as a double-blind, randomized, placebo-controlled study. Thirty-six women aged >/=50 years with acute lower back pain participated in this study. They were randomly divided into two treatment groups according to whether they received a placebo or a weekly trigger point injection of elcatonin (20 units). They were observed for 5 weeks and the extent of pain at motion and at rest according to the visual analog scale (VAS) was evaluated. The mean VAS scores for the elcatonin group were then compared with those of the placebo group.

Results: There were no statistically significant differences in the mean VAS scores for pain at rest between the two groups during the 5-week treatment course. However, the mean VAS scores for motion pain in the elcatonin group were significantly lower than those in the placebo group at the third, fifth and sixth weeks.

Conclusions: Elcatonin injection (20 units) significantly relieved motion pain in the lower back in postmenopausal women after three weeks of treatment. This analgesic effect continued for the subsequent 3 weeks.

No MeSH data available.


Related in: MedlinePlus